Skip to search formSkip to main contentSkip to account menu

ceftolozane

Known as: (6R,7R)-3-([3-Amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl)-7-([(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 
National Institutes of Health

Related topics

Related topics

9 relations
Anti-Bacterial AgentsBacterial InfectionsCephalosporinsceftolozane / tazobactam

Narrower (4)

CXA-101FR 264205Zerbaxaceftolozane sulfate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions
Background: Peritonitis is a common and serious complication of peritoneal dialysis (PD). PD-associated peritonitis (PDAP) caused… 
2018
2018
In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways
Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams… 
2018
2018
Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo‐Controlled, Multiple‐Dose Study
Ceftolozane/tazobactam is an antibacterial approved at 1.5 g (1g/0.5 g) every 8 hours (q8h); higher doses may provide additional… 
Review
2018
Review
2018
Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
2017
2017
Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
Background Optimization of the antibiotics for patients with infections due to MDR Pseudomonas aeruginosa (MDR-PA) often requires… 
2017
2017
Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa.
2017
2017
Retrospective Evaluation of the Use of Ceftolozane/Tazobactam at a Large Academic Medical Center
Background Ceftolozane/tazobactam is currently Food and Drug Administration–approved for the treatment of complicated intra… 
2016
2016
What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Antimicrobial resistance of bacterial infections is widely acknowledged to be one of the most serious health threats worldwide… 
2015
2015
Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa
Introduction: The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram… 
Review
2014
Review
2014
Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections
During the mid-nineties, 95–97% of intra-abdominal infection (IAI)- associated microbes were susceptible to commonly used… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)